Literature DB >> 27528063

Dietary Flaxseed Reduces Central Aortic Blood Pressure Without Cardiac Involvement but Through Changes in Plasma Oxylipins.

Stephanie P B Caligiuri1, Delfin Rodriguez-Leyva1, Harold M Aukema1, Amir Ravandi1, Wendy Weighell1, Randolph Guzman1, Grant N Pierce2.   

Abstract

UNLABELLED: In the year-long FlaxPAD clinical trial (Flaxseed for Peripheral Artery Disease), dietary flaxseed generated a powerful reduction in brachial systolic and diastolic blood pressure in patients with peripheral artery disease. Oxylipins were implicated as potential mechanistic mediators. However, the ability of flaxseed to impact central aortic hypertension, arterial stiffness, or cardiac performance was not investigated. Additionally, the relationship between central blood pressure (cBP) and oxylipins was not elucidated. Therefore, radial tonometry and pulse wave analysis were used to measure cBP and cardiac function in the FlaxPAD population (n=62). Plasma oxylipins were analyzed with high-performance liquid chromatography mass spectrometry. In patients with high blood pressure at baseline, the average decrease in central systolic and diastolic blood pressures versus placebo was 10 and 6 mm Hg, respectively. Flaxseed did not significantly impact augmentation index or other cardiac function indices. Alternatively, the data support several specific oxylipins as potential mediators in the antihypertensive properties of flaxseed. For example, every 1 nmol/L increase in plasma 16-hydroxyeicosatetraenoic acid increased the odds of higher central systolic and diastolic blood pressures by 12- and 9-fold, respectively. Every 1 nmol/L increase in plasma thromboxane B2 and 5,6-dihydroxyeicosatrienoic acid increased the odds of higher cBP by 33- and 9-fold, respectively. Flaxseed induced a decrease in many oxylipins, which corresponded with a reduced risk of elevated cBP. These data extend the antihypertensive properties of flaxseed to cBP without cardiac involvement but rather through oxylipins. This study provides further support for oxylipins as therapeutic targets in hypertension. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00781950.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  central blood pressure; flaxseed; hypertension; nutrition; oxylipins; peripheral vascular disease; pulse wave analysis

Mesh:

Substances:

Year:  2016        PMID: 27528063     DOI: 10.1161/HYPERTENSIONAHA.116.07834

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

1.  Flaxseed as an Anticardiotoxicity Agent in Breast Cancer Therapy.

Authors:  Ghassan Bkaily; Danielle Jacques
Journal:  J Nutr       Date:  2020-09-01       Impact factor: 4.798

Review 2.  Role of oxylipins in cardiovascular diseases.

Authors:  Mohammed A Nayeem
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

Review 3.  Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Sarah M Ajabnoor; Gabrielle Thorpe; Asmaa Abdelhamid; Lee Hooper
Journal:  Eur J Nutr       Date:  2020-10-21       Impact factor: 5.614

4.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-30

Review 5.  Bioactive Lipid Signaling in Cardiovascular Disease, Development, and Regeneration.

Authors:  Aaron H Wasserman; Manigandan Venkatesan; Aitor Aguirre
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

6.  Replacing Saturated Fat With Walnuts or Vegetable Oils Improves Central Blood Pressure and Serum Lipids in Adults at Risk for Cardiovascular Disease: A Randomized Controlled-Feeding Trial.

Authors:  Alyssa M Tindall; Kristina S Petersen; Ann C Skulas-Ray; Chesney K Richter; David N Proctor; Penny M Kris-Etherton
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

7.  Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Nicole Martin; Charlene Bridges; Julii S Brainard; Xia Wang; Tracey J Brown; Sarah Hanson; Oluseyi F Jimoh; Sarah M Ajabnoor; Katherine Ho Deane; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27

Review 8.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-07-18

Review 9.  Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Nicole Martin; Charlene Bridges; Julii S Brainard; Xia Wang; Tracey J Brown; Sarah Hanson; Oluseyi F Jimoh; Sarah M Ajabnoor; Katherine Ho Deane; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-07-18

10.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2020-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.